Market closed
Gossamer Bio/$GOSS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Gossamer Bio
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
Ticker
$GOSS
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
135
Website
Gossamer Bio Metrics
BasicAdvanced
$208M
-
-$0.32
1.96
-
Price and volume
Market cap
$208M
Beta
1.96
52-week high
$1.60
52-week low
$0.50
Average daily volume
1M
Financial strength
Current ratio
6.739
Quick ratio
6.531
Long term debt to equity
372.909
Total debt to equity
376.138
Interest coverage (TTM)
-5.23%
Management effectiveness
Return on assets (TTM)
-11.24%
Return on equity (TTM)
-90.26%
Valuation
Price to revenue (TTM)
1.972
Price to book
3.85
Price to tangible book (TTM)
3.85
Price to free cash flow (TTM)
-147.235
Growth
Earnings per share change (TTM)
-79.77%
3-year earnings per share growth (CAGR)
-54.04%
What the Analysts think about Gossamer Bio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Gossamer Bio stock.
Gossamer Bio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Gossamer Bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Gossamer Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Gossamer Bio stock?
Gossamer Bio (GOSS) has a market cap of $208M as of January 31, 2025.
What is the P/E ratio for Gossamer Bio stock?
The price to earnings (P/E) ratio for Gossamer Bio (GOSS) stock is 0 as of January 31, 2025.
Does Gossamer Bio stock pay dividends?
No, Gossamer Bio (GOSS) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Gossamer Bio dividend payment date?
Gossamer Bio (GOSS) stock does not pay dividends to its shareholders.
What is the beta indicator for Gossamer Bio?
Gossamer Bio (GOSS) has a beta rating of 1.96. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.